CN107074771B - 可溶性环氧化物水解酶抑制剂及其用途 - Google Patents

可溶性环氧化物水解酶抑制剂及其用途 Download PDF

Info

Publication number
CN107074771B
CN107074771B CN201580046202.2A CN201580046202A CN107074771B CN 107074771 B CN107074771 B CN 107074771B CN 201580046202 A CN201580046202 A CN 201580046202A CN 107074771 B CN107074771 B CN 107074771B
Authority
CN
China
Prior art keywords
compound
group
subject
pharmaceutical composition
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580046202.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN107074771A (zh
Inventor
张颖
A.D.基夫
C.杜梅林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
X Chem Inc
Original Assignee
X Chem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by X Chem Inc filed Critical X Chem Inc
Priority to CN202010138750.0A priority Critical patent/CN111454246A/zh
Publication of CN107074771A publication Critical patent/CN107074771A/zh
Application granted granted Critical
Publication of CN107074771B publication Critical patent/CN107074771B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201580046202.2A 2014-08-28 2015-08-26 可溶性环氧化物水解酶抑制剂及其用途 Expired - Fee Related CN107074771B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010138750.0A CN111454246A (zh) 2014-08-28 2015-08-26 可溶性环氧化物水解酶抑制剂及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462043275P 2014-08-28 2014-08-28
US62/043275 2014-08-28
PCT/US2015/046878 WO2016033150A1 (en) 2014-08-28 2015-08-26 Soluble epoxide hydrolase inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010138750.0A Division CN111454246A (zh) 2014-08-28 2015-08-26 可溶性环氧化物水解酶抑制剂及其用途

Publications (2)

Publication Number Publication Date
CN107074771A CN107074771A (zh) 2017-08-18
CN107074771B true CN107074771B (zh) 2020-03-20

Family

ID=55400481

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580046202.2A Expired - Fee Related CN107074771B (zh) 2014-08-28 2015-08-26 可溶性环氧化物水解酶抑制剂及其用途
CN202010138750.0A Pending CN111454246A (zh) 2014-08-28 2015-08-26 可溶性环氧化物水解酶抑制剂及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010138750.0A Pending CN111454246A (zh) 2014-08-28 2015-08-26 可溶性环氧化物水解酶抑制剂及其用途

Country Status (8)

Country Link
US (2) US10081616B2 (enExample)
EP (1) EP3186228A4 (enExample)
JP (1) JP2017525777A (enExample)
CN (2) CN107074771B (enExample)
AU (2) AU2015306643B2 (enExample)
CA (1) CA2958881A1 (enExample)
MA (1) MA40538A (enExample)
WO (1) WO2016033150A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111454246A (zh) * 2014-08-28 2020-07-28 X-化学有限公司 可溶性环氧化物水解酶抑制剂及其用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3600266B1 (en) * 2017-03-30 2022-07-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for use in the treatment of cardiovascular calcification
US20230071934A1 (en) * 2019-12-18 2023-03-09 Intra-Cellular Therapies, Inc. Novel uses
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3245950A1 (de) * 1981-12-24 1983-07-07 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur herstellung substituierter pyridine
WO2009151800A1 (en) * 2008-05-07 2009-12-17 Merck & Co., Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
WO2010080183A1 (en) * 2009-01-08 2010-07-15 The Trustees Of Columbia University In The City Of New York Potent non-urea inhibitors of soluble epoxide hydrolase
WO2013112751A1 (en) * 2012-01-25 2013-08-01 The Trustees Of Columbia University In The City Of New York Potent non-urea inhibitors of soluble epoxide hydrolase

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR037233A1 (es) * 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
JP2009528992A (ja) * 2006-02-16 2009-08-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性エポキシド加水分解酵素阻害剤として有益な置換ピリジンアミン化合物
CA2643859A1 (en) 2006-03-10 2007-09-20 Boehringer Ingelheim International Gmbh Soluble epoxide hydrolase inhibitors and methods of using same
CN102516115B (zh) * 2006-08-09 2016-05-11 史密丝克莱恩比彻姆公司 作为阿片样物质受体的拮抗剂或反向激动剂的新型化合物
CA2672373C (en) * 2006-12-19 2011-08-30 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
US20110306597A1 (en) * 2008-06-18 2011-12-15 James Michael Crawforth Nicotinamide Derivatives
TW201010997A (en) * 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
EP2149552A1 (de) * 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149551A1 (de) * 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
US20100113512A1 (en) * 2008-10-30 2010-05-06 Diane Michele Ignar Method of treatment using novel antagonists or inverse agonists at opioid receptors
WO2011091410A1 (en) * 2010-01-25 2011-07-28 Glaxos Smithkline Llc Trpv4 antagonists
US20130102600A1 (en) * 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
US20130102601A1 (en) * 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
US8809552B2 (en) * 2011-11-01 2014-08-19 Hoffmann-La Roche Inc. Azetidine compounds, compositions and methods of use
KR20150085045A (ko) * 2012-11-16 2015-07-22 메르크 파텐트 게엠베하 3-아미노시클로펜탄 카르복사미드 유도체
CN104016914B (zh) * 2014-05-27 2016-03-30 苏州科技学院 一种酰胺化合物的制备方法
JP2017525777A (ja) * 2014-08-28 2017-09-07 エックス−ケム，インコーポレーテッド 可溶性エポキシドヒドロラーゼ阻害剤及びこれらの使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3245950A1 (de) * 1981-12-24 1983-07-07 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur herstellung substituierter pyridine
WO2009151800A1 (en) * 2008-05-07 2009-12-17 Merck & Co., Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
WO2010080183A1 (en) * 2009-01-08 2010-07-15 The Trustees Of Columbia University In The City Of New York Potent non-urea inhibitors of soluble epoxide hydrolase
WO2013112751A1 (en) * 2012-01-25 2013-08-01 The Trustees Of Columbia University In The City Of New York Potent non-urea inhibitors of soluble epoxide hydrolase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111454246A (zh) * 2014-08-28 2020-07-28 X-化学有限公司 可溶性环氧化物水解酶抑制剂及其用途

Also Published As

Publication number Publication date
AU2015306643A1 (en) 2017-03-16
CN111454246A (zh) 2020-07-28
JP2017525777A (ja) 2017-09-07
EP3186228A1 (en) 2017-07-05
AU2020207828A1 (en) 2020-08-13
CN107074771A (zh) 2017-08-18
US20180362499A1 (en) 2018-12-20
US10081616B2 (en) 2018-09-25
EP3186228A4 (en) 2018-04-18
AU2015306643B2 (en) 2020-05-07
WO2016033150A1 (en) 2016-03-03
US20170240526A1 (en) 2017-08-24
MA40538A (fr) 2021-04-07
CA2958881A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
US10562870B2 (en) Prodrugs of riluzole and their method of use
US20240294489A1 (en) Low molecular weight protein degraders and their applications
EP4159211A1 (en) Compound exhibiting physiological activity such as antiviral activity
EP3677584A1 (en) Compound having bruton's tyrosine kinase (btk)-inhibition and degradation activity
AU2020207828A1 (en) Soluble epoxide hydrolase inhibitors and uses thereof
US10487087B2 (en) Positive allosteric modulators of the GLP-1 receptor
JP2020152641A (ja) リジン特異的脱メチル化酵素１阻害活性を有する新規化合物、その製造方法及びその用途
US10357497B2 (en) Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
JP2005504771A (ja) 抗腫瘍・抗癌剤としてのピペラジノン化合物と処置方法
WO2016039398A1 (ja) 含窒素複素環誘導体、神経保護剤及び癌治療用医薬組成物
JP2024511881A (ja) ＳＡＲＳ－ＣＯＶ－２ Ｍｐｒｏ阻害剤化合物
CA3021558A1 (en) Covalent btk inhibitors and uses thereof
WO2019079609A1 (en) SEH / PDE4 DOUBLE INHIBITORS AVAILABLE ORAL
EP3565817A1 (en) SMALL MOLECULE INHIBITORS OF NEUTRAL SPHINGOMYELINASE 2 (nSMase2) FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
WO2017175185A1 (en) Heteroaryl butanoic acid derivatives as lta4h inhibitors
WO2024089159A1 (en) Main protease inhibitors
US20160031838A1 (en) Smyd2 inhibitors
CN118251379B (zh) 铁死亡抑制剂及其用途
US20090281161A1 (en) Organic Compounds
WO2019046465A2 (en) THERAPEUTIC INDOLES
WO2020027723A1 (en) Bicyclic compounds as kinase modulators, methods and uses thereof
EP2185525B1 (fr) Dérivés de pyrazole 3,5-carboxylates, leur préparation et leur application en thérapeutique
WO2007144128A1 (en) Pyrrolidine compounds as renin inhibitors
JP2025526368A (ja) Ｉｒａｋ３のリガンド指向性分解分子としての置換ピラゾリル－ピリジニル化合物
KR100723539B1 (ko) 데포르밀라제 저해제, 이의 제조방법, 및 이를 포함하는조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200320

Termination date: 20210826